Drugs / SLV339
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00630279 | Feb 2008 → Mar 2009 | exocrine pancreatic insufficiency | Solvay Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SLV339 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00630279 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Microbial Lipase SLV339” NCT00630279 ↗ |
| Route | Oral | “oral, 150 mg/d, 7 days treatment” NCT00630279 ↗ |